Sample Template Example of Beautiful Excellent Professional Curriculum Vitae / Resume / CV Format with Career Objective, Job Description, Skills & Work Experience for Freshers & Experienced in Word / Doc / Pdf Free Download
Computational
Chemistry
University of Alabama
at Birmingham Birmingham , AL Mentor
University of Washington Seattle , WA
Princeton University
University of Georgia Athens , GA
United
States – Israel
Download Resume Format
Michael
Stroth
31 Ardenwald Road
California, FA 11215
Home: (735) 750-3025
Cell: (320) 720-5025
Summary Statement
Computational
scientist with nine year’s experience in the pharmaceutical industry and a
proven track record of research innovation and project management with
extensive expertise in informatics and modeling.
Positions Held
SRI International
Adjunct
Principal Scientist October
2011 – Present
Employment History
Locus Pharmaceuticals (Ansaris, February, 2009 –
May 2011) Blue Bell , PA
Senior Scientist August
2009 – Present
Scientist September 2008 – August 2009
Major Accomplishments
Project Leader
|
· Principle
Investigator on NIH grant-funded project to discover novel inhibitors of AMPK
using a fragment-based drug design approach. The most potent compound had improved
kinase selectivity and cellular potency relative to the most potent AMPK
inhibitor reported in the literature.
· Team Leader
for a collaboration between Ansaris and a major pharmaceutical company to
identify a hit through de novo fragment
based drug design for a challenging protein target. Designed compounds with
millimolar affinity and poor solubility that were improved to have 10
micromolar affinity and improved solubility. The binding of these compounds
was confirmed by NMR
· Identified
the Eli Lilly PD2 initiative as a potential collaboration
opportunity for Ansaris and led a team of chemists to identify historical
compounds from the archive to submit for screening. Several were of
sufficient interest for Eli Lilly to initiate dialogue into a potential
collaboration.
|
Structure-Based Drug Design
|
· Created
protein homology models to support fragment-based drug design in four kinase
programs where crystallographic information was unavailable for the target
proteins.
· Prospectively
used fragment-based drug design to design compounds that showed in vitro activity against a variety of
targets, including protein kinases and phosphatases.
· Participated
in two lead optimization projects with a major pharmaceutical collaborator
that resulted in the declaration of preclinical candidates.
|
Target Selection
|
· As a member
of the New Targets Team, carried out homology modeling and molecular dynamics
simulations, analyzed x-ray crystal structures, prioritized diverse subsets
of compounds from the corporate archive for high-throughput screening, and
evaluated the results of fragment binding simulations using the grand
canonical
|
ADMET Modeling
|
· Developed
and implemented a model to predict cellular permeability that was used to
prioritize compounds for testing in cellular assays and animal models.
· Placed
second in the 2008 QSAR World challenge to predict oral bioavailability.
|
Pharmacopeia Drug Discovery, Inc. Princeton , NJ
Department of
Molecular Modeling
Senior Scientist April 2008 – August 2008
Research Scientist March 2005 - March 2008
Major Accomplishments
ADME Modeling
|
· Created
statistical models for blood-brain barrier penetration, human intestinal
absorption, and serum protein binding that were deployed on scientists’ desktops
company wide. Model’s success led to mandatory use by chemists prior to
compound synthesis for a
· Placed
first in the 2007 QSAR World challenge to predict human intestinal
absorption.
|
Structure and Ligand-Based Drug Design
|
· Created
homology models that were used by chemists for the structure-based drug
design of compounds on three GPCR and two kinase lead optimization efforts.
· Created
target-focused virtual combinatorial libraries and QSAR models to prioritize
commercially available reagents for purchase.
· Developed
pharmacophore models for two GPCR programs.
· Applied a
novel flexible ligand alignment method to develop a binding hypothesis for
CXCR3 agonists.
|
Programming
|
· Wrote C++
code for chemical fingerprints and molecular descriptors that was
incorporated in desktop ADME modeling software company-wide.
· Wrote C++
code for Bayesian modeling software that was subsequently applied to a range
of problems in virtual screening and ADME modeling.
|
Technology Leader
|
· Led modeling
group effort to bring modern computational software in-house and apply them
to the drug discovery process. Based on key contributions to multiple project
teams, persuaded management to substantially increase the company’s
investment in computer hardware (purchase of a 64 processor cluster, $50,000).
|
Combinatorial Library Design
|
· Designed an
ECLiPSE library targeted for protein kinase inhibitors.
|
Novartis Institutes for Biomedical Research,
Inc. Cambridge , MA
Lead
Discovery Informatics June
2002–March 2005
Postdoctoral Fellow
Major Accomplishments
Virtual Screening
|
· Developed a
novel approach to enhance high-throughput docking using data fusion methods.
· Carried out
an extensive evaluation of high-throughput docking software programs. The
data was used by Novartis to purchase global licenses for two programs.
· Screened
Novartis’ compound archive and identified three sub-micromolar inhibitors of
Bcr-Abl kinase.
|
Programming
|
· Wrote C-Shell
and Perl scripts to parallelize computational jobs on a Linux cluster.
· Wrote
scripts to parse output files from five different docking programs and
analyze the results.
|
Education
Department of
Biochemistry and Molecular Genetics August 2002
Ph.D.
Biochemistry
Thesis: The
Structure and Dynamics of High Density Lipoprotein Particles
Cross-trained
in protein and small molecule x-ray crystallography with Dr. David Borhani.
Bachelor of Science in Biochemistry June 1997
Continuing Education
CHM 534:
Modern Methods for Organic Synthesis (audited) Princeton , NJ
Professors
David MacMillan and Erik J. Sorensen 2008
Brookhaven National Laboratory Upton , NY
Rapidata 2001 2001
8th
Annual American Crystallographic Association Summer Course 1999
Professional Affiliations
American
Chemical Society
Reviewing Responsibilities
Journal of
Chemical Information and Modeling
Combinatorial
Chemistry and High-Throughput Screening
Journal of
Computer-Aided Molecular Design
Drug
Discovery Today
Letters in
Drug Design and Discovery
Expert
Opinion on Therapeutic Patents
Other Activities
Advisory
Board, GTCbio 6th Annual Protein Kinases in Drug Discovery, Boston , MA May 26 – 27, 2011 .
Advisory
Board, GTCbio 5th Annual Protein Kinases in Drug Discovery, Boston , MA May 27 – 28, 2010 .
Session Chair,
Predictive ADME Session, eChemInfo, Bryn
Mawr College Philadelphia , PA October 17, 2008 .
Publications
Nedjai B, Li
H, Stroke IL, Wise EL, Webb ML, Merritt JR, Henderson I, Klon AE, Cole AG,
Horuk R, Vaidehi N, Pease JE. Small-Molecule Chemokine Mimetics Suggest a
Molecular Basis for the Observation that CXCL10 and CXCL11 are Allosteric
Ligands of CXCR3. Br.
Klon AE,
Konteatis Z, Meshkat SN, Zou J, Reynolds CH. Fragment and Protein Simulation
Methods in Fragment Based Drug Design. Drug
Dev. Res. 2011. 72. 130-137.
Meshkat S,
Klon AE, Zou J, Wiseman JS, Konteatis Z. Transplant-Insert-Constrain-Relax-Assemble
(TICRA): Protein-Ligand Complex Structure Modeling and Application to Kinases. J. Chem. Inf. Model. 2011.51. 52-60.
McGuinness
BF, Ho K-K, Stauffer TM, Rokosz LL, Mannava N, Kultgen SG, Saionz K, Klon A,
Chen W, Desai H, Rogers WL, Webb M, Yin J, Jiang Y, Li T, Yan H, Jing K, Zhang
S, Majundar KK, Srivastava V, Saha S. Discovery of Novel Quinolinone Adenosine
A2B Antagonists. Bioorg. Med. Chem. Lett.
2010. 20. 7414-7420.
Machrouhi
F, Ouhamou N, Laderoute K, Calaogan J,
Bukhtiyarova M, Ehrlich PJ, Klon AE. The Rational Design of a Novel Potent
Analogue of the 5’-AMP-Activated Protein Kinase Inhibitor Compound C with
Improved Selectivity and Cellular Activity. Bioorg.
Med. Chem. Lett. 2010. 20. 6394-6399.
Laderoute KR,
Calaoagan JM , Madrid
Klon AE.
Machine Learning Algorithms for the Prediction of hERG and CYP450 Binding in
Drug Development. Exp. Opin. Drug Metab.
Tox. 2010. 6, 821-833.
Ho KK,
Beasley JR, Belanger L, Black D, Chan JH, Dunn D, Hu B, Klon A, Kultgen SG,
Ohlmeyer M, Parlato SM, Ray PC, Pham Q, Rong Y, Roughton AL, Walker TL, Wright
J, Xu K, Xu Y, Zhang L, Webb M. Triazine and Pyrimidine Based ROCK Inhibitors with Efficacy in Spontaneous
Hypertensive Rat Model. Bioorg. Med.
Chem. Lett. 2009. 19, 6027-6031.
Klon AE.
Computational Models for Central Nervous System Penetration, Curr. Comput. Aided Drug Des. 2009. 5, 71-89.
Klon AE,
Bayesian Modeling in Virtual High-Throughput Screening. Comb. Chem. High Throughput Screen. 2009. 12, 469-483.
Anghelescu
AV, DeLisle RK, Lowrie JF, Klon AE, Xie X, Diller DJ, Technique for Generating
Three-Dimensional Alignments of Multiple Ligands from One-Dimensional
Alignments, J. Chem. Inf. Model. 2008. 48, 1041-1054.
Klon AE,
Diller DJ. Library Fingerprints: A Novel Approach to the Screening of Virtual
Libraries. J. Chem. Inf. Model. 2007. 47, 1354-1365.
Klon AE,
Lowrie JF, Diller DJ. Improved Naïve Bayesian Modeling of Numerical Data for the
Prediction of Absorption, Distribution, Metabolism and Excretion (ADME)
Property Prediction. J. Chem. Inf. Model.
2006. 46, 1945-1956.
Klon AE, Glick M, Davies JW. Application of Machine Learning to Improve the
Results of High-Throughput Docking Against the HIV-1 Protease. J. Chem. Inf.
Comput. Sci. 2004. 44, 2216-2224.
Ling L, Chen
J, Mishra VK, Kurtz JA, Cao D, Klon AE, Harvey SC, Anantharamaiah GM, Segrest
JP. Double Belt Structure of Discoidal High Density Lipoproteins: Molecular
Basis for Size Heterogenecity. J. Mol. Biol. 2004. 343,
1293-1311.
Klon AE, Glick M, Davies JW. The Combination of a Naive Bayes Classifier with
Consensus Scoring Improves the Enrichment of High-Throughput Docking Results. J.
Med. Chem. 2004. 47,
4356-4359.
Klon AE, Glick
M, Thoma M, Acklin P, J. Davies JW. Finding More Needles in the Haystack: A
Simple and Efficient Method for Improving High-Throughput Docking Results. J.
Med. Chem. 2004. 47,
2743-2749.
Glick M, Klon AE, Acklin P, Davies JW. Enrichment of Extremely
Noisy High Throughput Screening Data Using Naïve Bayes. J. Biomol. Screen. 2004.
9,
32-36.
Glick M, Klon
AE, Acklin P, Davies JW. Prioritization of High Throughput Screening Data of
Compound Mixtures Using Molecular Similarity. Mol. Phys. 2003. 101, 1325-1328.
Klon AE,
Segrest JP, Harvey SC. Molecular Dynamics Simulations on Discoidal HDL
Particles Suggest a Mechanism for Rotation in the Apo
A-I Belt Model. J. Mol. Biol. 2002. 324, 703-722.
Klon AE, Segrest
JP, Harvey SC. Comparative Models for Human Apolipoprotein A-I Bound to Lipid
in Discoidal High Density Lipoprotein Particles. Biochemistry. 2002. 41, 10895-10905.
Klon AE,
Héroux A, Ross LJ, Pathak V, Johnson CA, Piper JR, Borhani DW. Atomic
Resolution Structures of Human Dihydrofolate Reductase with NADPH and Two
Inhibitors. J. Mol. Biol. 2002, 320, 677-693.
Ahmadian M, Khare
NK, Klon AE, Borhani DW. Enantioselective
Route Phosphoribosyltransferase
Transition State
Klon AE,
Jones MK, Segrest JP, Harvey SC. Molecular Belt Models for the Apolipoprotein
A-I Paris and Milano Mutations. Biophys
J. 2000. 79, 1679-1685.
Segrest JP, Jones
MK, Klon AE, Sheldahl CJ, Hellinger M, De Loof H, Harvey SC. Apolipoprotein A-I
in Discoidal High Density Lipoprotein: A Detailed Molecular Belt Model. J. Biol. Chem. 1999. 274, 31755-31758.
Book Chapters
Konteatis ZD,
Klon AE, Zou J, Meshkat S. Computational Approach to De Novo Discovery of Fragment Binding for Novel Protein States. In Methods in Enzymology. Fragment-Based Drug
Design – Tools, Practical Approaches, and Examples March, 2011. 493,
357-380.
Patent Applications
Fendrich G,
Jacob SW, Klon AE, Manley PW. Three-dimensional structure of human c-Abl kinase
in complex with anti-tumor ligand, and use in drug discovery. U.S.
Invited
Presentations
A.E. Klon.
The Design of Potent and Selective Inhibitors of 5’-AMP-Activated Protein
Kinase. GTCbio 6th Annual Protein Kinases in Drug Discovery, May 26, 2011 , Boston , MA
A. E. Klon.
The Design of Potent and Selective Inhibitors of 5’-AMP-Activated Protein
Kinase Using CharretteTM. GTCbio 5th Annual Protein
Kinases in Drug Discovery, May
28, 2010 , Boston ,
MA
A. E. Klon.
Comparison of Machine Learning Algorithms to Predict ADME Properties Using
Chemical Descriptors and Molecular Fingerprints. eChemInfo, October 17, 2008 , Bryn Mawr
College Philadelphia , PA.
A. E. Klon. Bayesian Modeling of Numerical Data for ADME Property Prediction.
eChemInfo, October 18, 2007, Bryn Mawr
College, Philadelphia, PA.
A. E. Klon, M. Glick, J. W. Davies. Improving the Enrichment
of High-Throughput Docking Results Using Machine Learning. 228th ACS
National Meeting, August 24,
2004 , Philadelphia ,
PA.
A. E. Klon,
M. Glick, M. Thoma, J. W. Davies. Improving the Enrichment of High-Throughput
Docking Results Using Machine Learning. SciTegic User’s Group Meeting. January 28-30, 2004 , San Diego , CA
A. E. Klon,
M. Glick, M. Thoma, P. Acklin, J. W. Davies. Enrichment of High-Throughput
Docking Results Using Machine Learning.
Virtual Screening in Lead Discovery. September 7, 2003 , New York City
Other Presentations
J. Zou, S. Meshkat, Z. Konteatis, A. Klon, C. H. Reynolds. EfficientMethod
for Computing the Free Energies of Active Site Waters: Application to Drug
Discovery. August 22, 2010 ,
Boston , MA
A. E. Klon.
Virtual Fragment-Based Drug Design for Kinase Inhibitors. GTCbio 4th
Annual Protein Kinases in Drug Discovery, May 4, 2009 , Boston , MA
A. E. Klon. Comparison of Machine Learning Algorithms to
Predict ADME Properties Using Chemical Descriptors and Molecular Fingerprints.
236th ACS National
Meeting, August 20, 2008 ,
Philadelphia , PA.
A. E. Klon,
J. Lowrie, D. J. Diller. Improved Naïve Bayesian Modeling of Numerical Data for
ADME Property Prediction. 232nd ACS National Meeting, September 14, 2006 , San Francisco , CA
Posters
A. E. Klon,
F. Machrouhi, N. Ouhamou , K. Laderoute, J.
Calaogan, M. Bukhtiyarova, P. J. Ehrlich. The Successful Use of CharretteTM
to Prospectively Design Novel and Potent Inhibitors of 5’-AMP-Activated Protein
Kinase, AMPK. Biotech 2009, November
16, 2009 , Philadelphia ,
PA
A. E. Klon,
F. Machrouhi, N. Ouhamou , K. Ladehttps://docs.google.com/uc?id=1y_oGneQrFOybm6xmulut-r57yTZ95CBq&export=downloadroute, J.
Calaogan, M. Bukhtiyarova, P. J. Ehrlich. The Successful Use of CharretteTM
to Prospectively Design Novel and Potent Inhibitors of 5’-AMP-Activated Protein
Kinase, AMPK. eChemInfo, October
12 – 16, 2009 , Bryn
Mawr College Philadelphia , PA.
I. L. Str
e,
A. G. Cole, S. Simhadri, M.-R. Brescia, M. Desai, J. J. Zhang, J. R. Merritt,
A. E. Klon, K. C. Appell, I. Henderson, M. L. Webb. Identification of CXCR3
Receptor Agonists in Combinatorial Small-Molecule Libraries. Society for
Biomolecular Screening 12th Annual Conference. September, 2006, Seattle , WA
Q. K. Yue, A.
E. Klon, J. L. Jenkins, C. N. Parker, W. Wang, P. Margolis, D. Chen, Z. Yuan,
Chemoinformatic Strategies for the Discovery of Inhibitors of the Enzyme MurG.
Society for Biomolecular Screening 11th Annual Conference.
September, 2005, Geneva , Switzerland
A. E. Klon,
M. Glick, M. Thoma, P. Acklin, J. W. Davies. Enrichment of High-Throughput
Docking Results Using Naïve Bayes. 226th ACS National Meeting. September 9th, 2003 ,
New York , NY
A.E.
Klon, A. Heroux, L. J. Ross, V. Pathak, C. A. Johnson, J. R. Piper, D. W.
Borhani. Atomic Resolution Structures of Human Dihydrofolate Reductase
Complexed with NADPH and Two Inhibitors. American Crystallographic Association
Annual Meeting, July 22,
2001 , Los Angeles ,
CA
A.
E. Klon, J. P. Segrest, S. C. Harvey. UCSF/Biophysical Society Symposium
Honoring Peter A. Kollman. February
21st, 2002 , San
Fransisco , CA
Grants
NIH,
National Cancer Institute Grant CA132529, AMPK as a Target for Cancer Therapy, 08/21/08 – 08/31/10 .
Download Resume Format
.JPG)
.JPG)
0 comments:
Post a Comment